<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The addition of <z:chebi fb="0" ids="45783">imatinib</z:chebi> to high-intensity chemotherapy has improved the outcome of patients with Philadelphia chromosome (Ph)-positive <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) </plain></SENT>
<SENT sid="1" pm="."><plain>However, the possible long-term side effects of this combination are not yet known </plain></SENT>
<SENT sid="2" pm="."><plain>Development of new clonal abnormalities in complete cytogenetic remission after treatment with <z:chebi fb="0" ids="45783">imatinib</z:chebi> has been reported in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> but not in patients with Ph-positive ALL </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we present a patient with Ph-positive ALL who received hyperCVAD plus <z:chebi fb="0" ids="45783">imatinib</z:chebi> and achieved hematologic, cytogenetic, and major molecular responses </plain></SENT>
<SENT sid="4" pm="."><plain>The patient then developed <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and solitary central <z:mp ids='MP_0008912'>nervous</z:mp> system relapse of ALL </plain></SENT>
</text></document>